Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Feature|Articles|March 26, 2026
Exploring One-Time Gene Regulation Therapy EXT101 in Dravet Syndrome: The Phase 1/2 POLARIS Program
Author(s)Isabella Ciccone, MPH
The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.
Advertisement
Advertisement
Welcome to NeurologyLive®'s Clinical Trial in Focus. Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. This month’s spotlight is the phase 1/2 POLARIS program of EXT101 (Encoded Therapeutics), an adeno-associated virus (AAV)-mediated candidate for gene regulation therapy, for the treatment of SCN1A+ Dravet syndrome (DS).
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Here's some of what is coming soon to NeurologyLive® this week.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Advertisement
Advertisement